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Abstract
Subcellular organelles including mitochondria and endoplasmic reticulum are now con-
sidered as one major target for many therapeutic approaches. In fact, recent evidence has 
uncovered the roles of mitochondria as a direct inflammatory and immune controller and 
contributor to the diseases by metabolic dysfunction and/or their abnormal dynamics. In 
addition, one of the important subcellular organelles, endoplasmic reticulum, also plays 
as an immune responder in several diseases including bronchial asthma. Recently, we 
have reported that the endoplasmic reticulum stress and mitochondrial reactive oxygen 
species (ROS) contribute to the pathogenesis of steroid-resistant severe bronchial asthma 
through the modulation of immune responses such as production of regulatory cytokines 
and NLRP3 inflammasome activation. These findings indicate that the subcellular organ-
elles and their complex can be a promising target for the development of novel therapeu-
tic strategies including medicines to cure severe asthma. This chapter is aimed to present 
the state-of-art information regarding the role of subcellular organelles in severe asthma.
Keywords: subcellular organelles, mitochondria, endoplasmic reticulum, 
inflammasome, severe asthma
1. Introduction
Subcellular organelle is a specialized subunit within a cell that has a specific function. Individual 
organelles are usually separately enclosed within their own lipid bilayers [1]. Specifically in 
eukaryotic cells, the organelles include nucleus, mitochondrion, endoplasmic reticulum (ER), 
Golgi apparatus, peroxisome, and lysosome which are found in the cytoplasm, a viscous liquid 
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found within the cell membrane that houses the organelles and is the location of most of the action 
happening in a cell. Each organelle plays the specific functions such as DNA storage, energy pro-
duction, production of lipid and proteins, export of the proteins from the cells, protein modifica-
tion, and destruction of lipid and protein, respectively.
Among them, ER is the largest organelle in the cell and is a major site of protein synthesis and 
transport, protein folding, lipid and steroid synthesis, carbohydrate metabolism, and calcium 
storage [2–6]. One of the most prominent functions of the ER is protein synthesis. When ER is 
overloaded by increased demand in protein folding, cells initiate an adaptive response called 
unfolded protein response (UPR). In addition, the ER’s secretory pathway of its products and 
the ER-associated degradation (ERAD) pathway try to keep the homeostasis with full activ-
ity [7, 8]. ER stress can be developed, if ER fails to overcome the overloads and UPR are not 
able to make the ER adapt to the stressful conditions, despite all ER’s efforts and adaptive 
responses. Recent considerable studies have demonstrated that ER stress is associated with 
the pathogenesis of several diseases such as neurodegenerative disorders, metabolic disor-
ders, cardiovascular diseases, malignancies, and respiratory disorders [9–12]. More specifi-
cally, in severe asthma or steroid-resistant asthma, the role of ER stress has been highlighted 
in terms of regulation and interaction of various signaling pathways linked to steroid resis-
tance [13]. In addition, nowadays, changes of ER shapes and structure responded to ER stress 
are emerging as one of pathogenic mechanisms regarding several disorders [14].
Mitochondria are energy-producing organelles which are dynamic and possess mitochon-
drial own DNA distinct from nuclear genome [15]. Basically, they are in charge of the syn-
thesis and catabolism of metabolites, generation and detoxification of reactive oxygen species 
(ROS), apoptosis, regulation of calcium, and generation of adenosine triphosphate (ATP) by 
oxidative phosphorylation [16]. Recently, a novel role for mitochondria has been revealed in 
various disorders such as infectious diseases, neurodegenerative diseases, cerebrovascular 
diseases, and metabolic diseases, especially in the association of innate immune and inflam-
matory responses [16–19]. In addition, our recent study has revealed that exceed generation 
of mitochondria ROS and alteration of mitochondrial DNA induced steroid-resistant neutro-
philic asthmatic features through the activation of NLRP3 inflammasome in mice [20]. More 
interestingly, mitochondria are highly motile organelles. In fact, we know that mitochondria 
actively travel along the microtubule network in neurons and accumulate at sites of high-
energy demands [21]. These mitochondrial dynamics and morphological changes are through 
constitutive cycles of fusion and fission [22]. Nowadays, impaired processes of mitochondrial 
dynamics have been accepted as a pathogenic contributor to various disorders, including 
lung diseases [23, 24].
The last decades have witnessed an explosion in the elucidation of the causative mechanisms 
implicated in bronchial asthma, especially severe or steroid-resistant asthma; however, the 
treatment of asthmatic patients is still challenging. One of the reasons can be that many newly 
developed therapeutic tools are single-targeted and linked to the shortage of broad clinical 
effect, although they might be effective in asthmatic patients with specific phenotypes. On 
the other hand, drugs with more widespread effects (e.g., kinase inhibitors) might be more 
effective pharmacologically, whereas the potential risk of side effects might increase [25]. 
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Therefore, novel treatments should be considered to target the aspects of the multiple under-
lying allergic/immune/inflammatory processes and minimize the adverse effects on other sys-
tems. In terms of this point, targeting subcellular organelles, especially ER and mitochondria, 
has a strong competitive power for the development of future medications of asthma, espe-
cially steroid-resistant asthma, since restoration of their abnormal function to normal physi-
ologic status of each subcellular organelle is going without serious adverse effects unlikely to 
the existing therapeutic approach of blocking or eliminating the pathogenic targets.
2. Severe asthma and its heterogeneity
For many years, the term severe asthma has been used interchangeably with other similar 
terms, and considerable effort has been concentrated to be uniform in the term and concept. 
Several academic societies and research groups have suggested the definition of severe asthma 
such as European Respiratory Society (ERS), American Thoracic Society (ATS), World Health 
Organization (WHO), and British Thoracic Society (BTS)/Scottish Intercollegiate Guideline 
Networks (SIGN) [26–30]. In various definitions of severe asthma with little differences, there 
is a common ground that severe asthma can be defined as a failure to achieve control with 
maximum doses of inhaled corticosteroid therapies [31]. Taken together, severe asthma con-
tains the existing disease entities; steroid-insensitive asthma, steroid-resistant asthma, dif-
ficult asthma, and refractory asthma, and these subsets of asthmatics have been estimated up 
to 5–10% of all asthmatics.
Although there are still many different definitions for severe asthma available and difficulties 
in making an accurate definition for severe asthma, numerous data based on these defini-
tions consistently demonstrate the heterogeneity of severe asthma in populations with asthma 
[32, 33]. In fact, in 2001, the National Heart, Lung, and Blood Institute initiated the Severe 
Asthma Research Program (SARP) to identify and characterize not only a large number of sub-
jects with severe asthma but also to compare these subjects with those with mild to moderate 
asthma [34]. In the SARP adult clinical cluster analysis, five different groups of subjects with 
asthma were identified who differ in clinical and pathophysiologic parameters [33]. These 
five asthma phenotypes differ in lung function, age of asthma onset and duration, atopy, sex, 
symptom frequency, medication use, and health-care utilization. Clusters 1, 2, and 4 reflect 
the spectrum of allergic asthma from mild to severe airflow obstruction. The majority of these 
patients have early-onset disease, with history of atopy confirmed by skin prick testing and 
elevated total serum IgE. By contrast, Clusters 3 and 5 reflect the spectrum of adult-onset 
asthma characterized by older patients with less atopy, yet, high health-care utilization and 
poor quality of life [33]. The SARP clinical heterogeneity, even in severe asthma group, can 
provide a basis for the needs to investigate the different molecular and biological mechanisms 
and different therapeutic approaches for the patients with severe asthma. In addition, SARP 
cluster analysis revealed inflammatory heterogeneity through the evaluation of blood and 
sputum inflammatory cells. In addition, the data suggested that sputum eosinophils were 
increased in Cluster 4 subjects with severe allergic asthma, whereas both eosinophils and neu-
trophils were increased in subjects from Cluster 5 [33]. A sequential study has reported that 
Subcellular Organelles in Immune Responses of Severe Asthma: The Roles of Mitochondria and…
http://dx.doi.org/10.5772/intechopen.75148
107
grouping of subjects based on their sputum inflammatory cell profile identified four groups 
of subjects with distinguishing clinical characteristics [35]. For instance, patients showing both 
eosinophil (≥2%) and neutrophil (≥40%) predominant pattern, called as mixed granulocytic 
pattern, had the most severe asthma with severe chronic airflow obstruction and increased 
symptoms with high health-care utilization. In addition, according to this paradigm, all five 
clinical clusters of SARP showed all four patterns of sputum inflammatory profiles without a 
dominant pattern in any one cluster [34]. The lack of association between the clinical clusters 
and sputum inflammatory cell patterns does not only make the heterogeneity of severe asthma 
more complex but also emphasize that future analyses must incorporate clinical, physiologic, 
and inflammatory measures into one analysis [36].
Very recently, an interesting study of cluster analysis data has been released using U-BIOPRED 
(Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) severe asthma cohort 
[37]. In this study, three transcriptome-associated clusters (TACs) were defined: TAC1 char-
acterized by immune receptors IL33R, CCR3, and TSLPR, TAC2 characterized by interferon-, 
tumor necrosis factor (TNF)-α, and inflammasome-associated genes, and TAC3 characterized 
by genes of metabolic pathways, ubiquitination, and mitochondrial function. Subjects with 
severe asthma were classified into these three clusters based on their sputum transcriptomics 
data. Each TAC group exhibits their own differential clinical features: one Th2-high eosin-
ophilic phenotype TAC1 and two non-Th2 phenotypes TAC2 and TAC3, characterized by 
inflammasome-associated and metabolic/mitochondrial pathways, respectively. This analytic 
approach is unlikely to previous ones such as SARP which showed the lack of association 
between the clinical clusters and sputum inflammatory cell patterns. Considering that clus-
tering using clinical features alone has not yielded information on the underlying biology 
as similar inflammatory cell profiles have been seen between these clinical clusters [34], this 
study is worthy to approach with the unconventional direction from inflammatory or biologic 
clustering to clinical phenotyping. This approach provides a fresh framework on which to 
phenotype asthma and a more precise targeting of specific treatments [38]. Specifically, the 
development of novel medications has been poorer, targeting non-Th2 or non-type-2 severe 
asthma than Th2 or Type-2 severe asthma. In terms of this issue, this novel-clustering analysis 
data are expected to be helpful for the development of the medicines targeting non-type 2 
asthmatics. In fact, two non-Th2 phenotypes TAC2 and TAC3 are associated with inflamma-
some and mitochondrial pathway, respectively. In addition, while the majority of subjects 
in TAC2 group show neutrophilic predominant inflammatory pattern, the subjects in TAC3 
group can be further divided into paucigranulocytic, eosinophilic, and neutrophilic pattern 
subgroups. Interestingly, the differential characteristic of eosinophilic TAC3 subjects from 
Th2-type TAC1 subjects is the elevated levels of inflammasome, suggesting that non-Th2 type 
asthma can also have eosinophilic-dominant inflammation partly through the activation of 
inflammasome.
Considering nowadays the concept of severe asthma and heterogeneity, the improvement 
of the detailed characterization of the patients is required to achieve appropriate therapeutic 
responses for severe asthma. It is expected that the correct determination of phenotype and 
molecular endotype leads to more effective precision medicine for severe asthma.
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3. ER stress in severe asthma
As introduced, ER is a specialized organelle that plays as an important regulator of protein 
homeostasis in cells of an organism. The ER is rich in chaperones and enzymes that help to 
fold the protein properly. ER chaperones and enzymes are fragile to various stresses; thus 
several stressful or pathologic conditions (e.g., disease situation) may lead to the impaired 
ER protein-folding capacity leading to the accumulation of misfolded and unfolded proteins 
in the ER lumen. This out-of-controlled state of ER is usually called as ER stress [13, 39, 40].
Three ER transmembrane sensors are inositol-requiring enzyme 1α (IRE1α), double-stranded 
RNA-dependent protein kinase (PKR)-like ER kinase (PERK), and activating transcription 
factor 6 (ATF6). The functions of the ER membranous proteins include monitoring protein 
homeostasis of ER lumen and activation of canonical UPR pathways to deliver the informa-
tion on the ER status to cytoplasm [40, 41]. According to the classic model of the activation 
of UPR, in basal conditions, these three transmembrane proteins are bound by a chaperone, 
BiP/glucose-regulated protein 78 (GRP78) [42, 43]. The development of ER stress causes the 
separation of BiP from these UPR sensors bound. The activation of IRE1α and PERK is associ-
ated with the dimerization and auto-phosphorylation, while in case of ATF6, its translocation 
to the Golgi is required to get activated [7]. Activated forms of proteins mitigate ER stress 
through the reduction of protein synthesis, the enhancement of protein degradation, and the 
induction of production of ER chaperones. When the protective process fails to resolve ER 
stress, the cell is prepared for apoptosis which is also one of the biological protective mecha-
nisms [44]. Recently, in addition to these canonical UPR, noncanonical aspects of UPR confer 
cells to interconnect protein homeostasis-related cellular apparatus to a wide array of cellular 
events including immunity and inflammation through various mechanisms, as substantially 
reviewed elsewhere [45, 46].
In addition, the complex roles of ER including protein synthesis and lipid synthesis, calcium 
regulation, and interactions with other organelles are reflected in an equally complex physical 
architecture. The ER is composed of a continuous membrane system that includes the nuclear 
envelope and the peripheral ER, defined by flat sheets and branching tubules [14]. While it is 
generally known how the basic shapes of ER sheets and tubules are determined, it is relatively 
unclear how changes in the shape or the ratio of sheets to tubules occur in response to spe-
cific cellular signals. In several conditions, increasing ER loads and ER stress such as mitosis, 
changes of ER structure, and shapes are noted. In fact, recent studies showed that splicing of 
XBP1 is activated during meiosis in both Xenopus and budding yeast [47, 48], suggesting that 
changes in ER structure during meiosis could be linked to the ER stress response. However, to 
date, it is remained unclear whether ER stress induces immediate restructuring of ER or not. 
In the same vein, it has not yet been determined whether the activation of ER stress-respon-
sive-signaling pathways results in a modification of structural components of the ER [14].
Accumulating data have indicated that ER stress and UPR link to major inflammatory and 
stress-signaling networks including the nuclear factor kappa B (NF-κB) pathway and oxida-
tive stress. Recent studies have unveiled the role of ER stress in the pathogenesis of various 
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pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), 
idiopathic pulmonary fibrosis, and acute lung injury [9, 49–52].
As for bronchial asthma including severe form, the role of ER stress has been reviewed else-
where [13, 40, 52]. In particular, neutrophilic steroid-resistant severe asthma animal model, 
which is similar to human TAC2 group, exhibited the significant increases in ER stress mark-
ers, GRP78 and CCAAT/enhancer binding protein-homologous protein (CHOP), as well as 
UPR-related proteins in lung tissues and BAL cells [9]. The mice showed typical asthmatic 
manifestations including bronchial hyperresponsiveness and airway inflammation which 
were not attenuated by the treatment with oral dexamethasone. Intriguingly, an ER stress 
regulator, 4-phenylbutyric acid (4-PBA), effectively attenuated steroid refractory asthmatic 
features as well as increases in ER stress linked to NF-κB activation which induces various 
severe inflammatory/immune responses in the lung. In addition, 4-PBA dramatically reduced 
the increased expression of IL-17, while it further enhanced the increase in IL-10 levels, lead-
ing to the attenuation of steroid-resistant asthmatic features. In another recent study using the 
same animal model [20], the activation of NLRP3 inflammasome was measured. The results 
revealed that NLRP3 inflammasome was significantly activated in lung tissues and BAL 
cells from neutrophilic-dominant severe asthma murine model and that the severe asthmatic 
symptoms were dramatically attenuated by the blockade of IL-1β which is one of major effec-
tor cytokines by NLRP3 inflammasome activation. A more recent study using another neu-
trophilic-dominant steroid-resistant asthma animal model and human data also has revealed 
the significant role of NLRP3 inflammasome in the pathogenesis of neutrophilic-dominant 
severe asthma [53]. These findings suggest that the neutrophilic-dominant steroid-resistant 
or severe asthma animal models can represent the TAC2 group of human severe asthma char-
acterized by IFN, TNF-α, and inflammasome-associated genes and that ER stress can be more 
associated with this clustered asthma. A recent study has also demonstrated that ER stress 
inducer, tunicamycin, aggravates ER stress in mouse bronchial epithelial cells and increased 
the expression of inflammation indicators such as IL-6, IL-8, and TNF-α in lung tissues of 
neutrophilic severe asthmatic mice [54]. The double-stranded RNA (dsRNA)-activated ser-
ine/threonine kinase R (PKR) is well characterized as an essential component of the innate 
antiviral response. In view of the relation with ER stress, PKR phosphorylates e-IF2α, one 
of the branches for UPR, and at the same time, ER stress activates PKR which stimulates 
various inflammatory-signaling pathways [55, 56]. With this background, a recent interesting 
study showed that poly (I:C)-induced exacerbation of neutrophilic severe asthmatic mice was 
closely associated with PKR phosphorylation as well as increased ER stress in lung tissues 
including bronchial epithelial cells [56].
In addition to neutrophilic severe asthmatic phenotype, eosinophil-dominant severe asthma 
with fungal sensitization also showed the significant elevation of ER stress in mice [57]. In this 
study, Aspergillus fumigatus extract-inhaled mice showed typical asthmatic manifestations 
including eosinophilic airway inflammation and airway hyperresponsiveness which were not 
responded to treatment with oral steroid, while all asthmatic features and increased ER stress 
were very well controlled by 4-PBA, suggesting that ER stress is linked to the pathogenesis 
of eosinophilic-dominant severe asthma as well as neutrophilic-dominant one. Meanwhile, 
this animal model appeared to represent the TAC3 human severe asthma group. As described 
Asthma Diagnosis and Management - Approach Based on Phenotype and Endotype110
earlier, TAC3 is characterized by genes of metabolic pathways, ubiquitination, and mito-
chondrial function, and the subjects of TAC3 exhibit various inflammatory cell types includ-
ing paucigranulocytic, eosinophilic, and neutrophilic pattern subgroups. Thus, this fungal 
extract-inhaled eosinophilic severe asthma murine model can be considered as an eosino-
philic pattern TAC3, non-Th2 eosinophilic asthma. Actually, in this study, mitochondrial ROS 
was significantly increased in the lung from A. fumigatus extract-inhaled mice [57].
These observations suggest that ER stress plays a critical role in the pathogenesis of vari-
ous phenotypes of severe asthma including neutrophilic, eosinophilic, and viral infection-
related types, supporting that the ER stress-targeting strategy seems to be able to overcome 
the  steroid resistance in severe asthma.
4. Mitochondria in severe asthma
Asthma is characterized by ongoing inflammation and accompanied by increased oxidative 
stress and subsequent lung injury. ROS production, which leads to oxidative stress, is one 
of critical features in chronic airway disorders [58]. Two major sources of ROS induced by 
external stimuli are mitochondria and the Nox family of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase in vivo. Besides, the mitochondrial respiratory chain is consid-
ered to be an important part of ROS production within most cells [59]. In addition, the con-
siderable interplay between mitochondria and ER in several respiratory disorders has been 
demonstrated [59, 60]. In fact, fungal extract-inhaled mice exhibiting features of eosinophilic 
severe asthma or representing eosinophilic TAC3 showed significant increases in the produc-
tion of mitochondrial ROS in BAL cells [57]. A. fumigatus extract-stimulated tracheal epithe-
lial cells from the mice also markedly more generated mitochondrial ROS compared to the 
control cells [57]. In addition, treatment with NecroX-5, a potent mitochondrial ROS inhibi-
tor, effectively attenuated increases in mitochondrial ROS in BAL cells, reduced increases in 
GRP78 and CHOP in lung tissues from A. fumigatus extract-inhaled mice, and ameliorated 
pathophysiologic features of fungal extract-induced eosinophilic severe asthma. In addition 
to eosinophilic severe asthma, recent experimental data using ovalbumin (OVA) and lipo-
polysaccharide (LPS)-sensitized and OVA-challenged mice (OVA-LPS mice) representing 
TAC2 revealed that the increased generation of mitochondrial ROS and the alteration of mito-
chondrial DNA induced steroid-resistant neutrophilic asthmatic features through the activa-
tion of NLRP3 inflammasome in lung and that the restoration of mitochondrial ROS levels 
using mitochondrial-specific ROS scavenger dramatically attenuated steroid-resistant airway 
hyperresponsiveness and inflammation in mice [20]. These findings suggest that mitochon-
drial metabolic dysfunctions such as mitochondrial ROS generation and mitochondrial DNA 
damage are linked to other subcellular organelles (e.g., ER) and immunologic complex (e.g., 
inflammasome) in the pathogenesis of steroid-resistant asthma and that mitochondrial ROS 
plays a key role in the induction and maintenance of neutrophilic and eosinophilic steroid-
resistant severe asthma. As supporting data, when N-acetylcysteine (NAC), which is a repre-
sentative conventional antioxidant, was administered to both types of steroid-resistant severe 
asthma murine models, for example, eosinophilic and neutrophilic types, NAC did not affect 
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steroid-resistant asthmatic features, mitochondrial ROS generation, and NLRP3 inflamma-
some activation (unpublished data), suggesting the importance of the role of mitochondrial 
ROS generation in the pathogenesis of steroid-resistant severe asthma as well as one of causes 
for the previous failures in the clinical trials for asthma patients to evaluate the effects of vari-
ous conventional antioxidants.
Like this, mitochondria perform many roles beyond energy production, including the genera-
tion of ROS, redox molecules, and metabolites; regulation of cell signaling and cell death; and 
biosynthetic metabolism [61–63]. Thanks to these observations, mitochondria have recently 
become a promising target for the treatment of various inflammatory disorders, including 
bronchial asthma. However, most studies regarding mitochondria as a pathogenic contribu-
tor have dealt with mitochondrial metabolic dysfunction or mitochondrial genetic abnor-
mality. As introduced, mitochondria are not static, highly dynamic in cells, and change the 
morphology.
Mitochondrial morphology is controlled by large guanosine triphosphatases in the dynamin 
family [64]. Among them, mitofusins 1 and 2 (MFN-1 and MFN-2) and optic atrophy protein 
1 (OPA-1) are essential mediators of mitochondrial fusion [65]. By contrast, fission requires 
dynamin-related protein 1 (DRP-1) to be recruited from the cytosol to the mitochondrial sur-
face [66]. Mitochondrial fission is known to be prevalent in diseased cells, with subsequent 
elimination of damaged mitochondria via mitophagy [67]. By contrast, mitochondrial fusion 
inhibits apoptotic cell death [22]. In fact, several reports have demonstrated that increased 
mitochondrial fission and decreased fusion are observed in cells from various lung diseases 
such as lung cancer [68, 69]. Interestingly, our preliminary data have revealed that mitochon-
drial dynamics were out of control in A. fumigatus extract-inhaled mice, and the restoration of 
abnormal mitochondrial dynamics could attenuate the steroid-resistant airway inflammation 
and airway hyperresponsiveness (unpublished data), providing the novel concept that a ther-
apeutic strategy targeting mitochondrial dynamics can overcome steroid resistance in severe 
asthma. However, we are only beginning to evaluate and understand the related mechanisms 
and the role of mitochondrial dynamics in the pathogenesis of severe asthma. More future 
researches and studies are needed to support the role of mitochondria in the pathogenesis 
of severe asthma. In addition, the identification of the specific phenotype and/or endotype 
related to mitochondrial metabolic and morphologic dysfunction is eagerly required for the 
patient-oriented treatment or the precision medicine of severe asthma.
5. Potential clinical biomarkers and therapies related to 
mitochondria and ER
Biomarkers may facilitate the diagnosis and classification of severe asthma, predict efficacy 
of specific therapies, and assess medication response. Based on the data, to date, there are 
some potential biomarkers related to ER, mitochondria, and inflammasome in severe asthma. 
More specifically, the biomarker candidates are considered as the biomarkers for the predic-
tion of efficacy of the subcellular organelle targeting therapies and for assessment therapeutic 
responses.
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In fact, ER stress markers, GRP78 and CHOP, have been measured in BAL fluid from asthmatic 
patients [9]. Very interestingly, the levels were increased in BAL fluid from asthmatics compared 
to the levels from the healthy persons. The asthmatics were composed of patients who had been 
diagnosed and treated for asthma for more than 3 months with inhaled corticosteroid or com-
bined inhaled corticosteroid and beta-β
2
-agonist. In addition, the patients exhibited uncontrolled 
asthmatic symptoms scored below 19 points by asthma control test (ACT) scoring system despite 
the standard treatment including inhaled corticosteroid. Although the protein expression levels 
of GRP78 and CHOP were not correlated with the lung function, the protein expression reflected 
the asthmatic-controlled status in humans supported by the data from animal experiments, in 
which steroid-responded asthmatic mice showed the decrease in the expression levels of GRP78 
and CHOP in lung tissues by the treatment of steroid, while the steroid-resistant asthmatic mice 
were refractory to the treatment with steroid in terms of the protein levels. When an ER stress 
inhibitor, 4-PBA, was administered to the steroid-resistant asthmatic mice, the levels of GRP78 
and CHOP were substantially reduced in lung tissues and BAL cells with the attenuation of 
asthma symptoms [9]. These findings suggest the potential of the use of GRP78 and CHOP as 
biomarkers, classifying the patients into steroid-responsive group and steroid-resistant group 
after the standard treatment including inhaled corticosteroid as well as predicting or monitoring 
the therapeutic responses of ER stress inhibitor as a medication for severe asthma.
Mitochondrial ROS can be another biomarker candidate. In asthma, there is an elevated airway 
expression of products of oxidative stress. Actually, exhaled breath condensate levels of oxi-
dative stress-related biomarkers, such as hydrogen peroxide (H
2
O
2
), nitrite/nitrate, 8-isopros-
tane, and others vary with asthma exacerbations, disease severity, and medication use [70]. 
As mentioned earlier, mitochondrial ROS may be a more critical player in the pathogenesis 
of severe asthma compared to general or total cellular ROS generation. Nowadays, several 
tools including simple detection kits and staining indicators have been introduced for mea-
suring the specific mitochondrial ROS levels which distinct from the total cellular ROS gen-
eration in vivo. Thus, in addition to cellular ROS, mitochondrial ROS in various biological 
samples such as exhaled breath condensate, sputum, and BAL fluid can be expected to be one 
of biomarkers of the next generation for the diagnosis of severe or steroid-resistant asthma. 
Moreover, the studies using recently developed mitochondrial ROS inhibitor, NecroX com-
pounds, have reported the excellent efficacy of this chemical as a potent and specific mito-
chondria-targeted antioxidant in several disease models [71–75]. Even in human studies, a 
phase II clinical trial is currently being performed to evaluate the efficacy, safety, and phar-
macokinetics of intravenous injection of NecroX-7 immediately before percutaneous coro-
nary intervention in patients with myocardial infarction (ClinicalTrials.gov; NCT02770664). 
Therefore, it can be hypothesized to consider that NecroX compounds may be developed as a 
novel therapeutic agent to control or cure the steroid-resistant severe asthma in future.
Furthermore, mitochondrial ROS is closely associated with the assembly of inflammasome, 
specifically NLRP3 inflammasome, which is formed by various stimuli in the inflammatory 
state. NLRP3, one of the cytosolic pattern recognition receptors, plays as one of the components 
of the inflammasome and recognizes a variety of inflammatory stimuli, pathogen-associated 
molecular pattern molecules (PAMPs), and damage-associated molecular pattern molecules 
(DAMPs) in cells. Subsequently, the assembled and activated NLRP3 inflammasome controls 
the production of important pro-inflammatory cytokines such as IL-1β and IL-18 [76]. Two 
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common events that are required for these activators of the NLRP3 inflammasome are potas-
sium efflux and ROS generation [77]. Recent interesting studies have revealed that steroid-
resistant neutrophilic asthmatic manifestations were significantly controlled by the NLRP3 
inflammasome activation, and the severe asthmatic symptoms were dramatically attenuated 
by the blockade of IL-1β or inflammasome inhibitor, MCC950 [20, 53]. Moreover, increased 
NLRP3 and IL-1β sputum gene expression were strongly associated with increasing asthma 
severity in humans, suggesting that the NLRP3 inflammasome is important in human disease 
as well [53]. In addition, the protein expression levels of NLRP3 and caspase-1 were more 
increased in BALF from uncontrolled asthmatics compared to healthy subjects [20]. Taken 
together, these data suggest the potential of NLRP3, IL-1β, or caspase-1 to use as diagnostic 
and therapeutic biomarkers in respiratory specimens and urge to perform the translational or 
clinical studies regarding this issue. In addition, until now, there are no interventional clinical 
data applying the agents targeting NLRP3 inflammasome such as MCC950 in steroid-refrac-
tory severe asthma; however, it can be a very promising target for the control of severe asthma.
Altogether, it is clear that there are huge needs for further researches and future translational 
and clinical studies to use the candidate markers and therapeutic agents related to subcellular 
organelles in clinical practice.
6. Conclusion and future directions
Severe asthma is characterized by uncontrolled symptoms and recurrent exacerbation with 
excessive chronic airway inflammation despite adequate and even maximum treatment with 
the current medications. Although multiple factors can cause poor responses and underlying 
pathogenic differences are being revealed explaining the various therapeutic responses includ-
ing steroid insensitivity, effective therapeutic modalities for severe asthma still remain as a 
major unmet need [78]. To overcome these current obstacles, cluster analysis and research for 
the heterogeneity of severe asthma are actively ongoing. Recent unconventional approach to 
define the clusters of subjects with severe asthma using TACs seems to be more helpful for the 
development of precision medicine for severe asthma compared to conventional clinical feature-
based clusters, although more future supporting researches are needed. In addition, the hetero-
geneity of severe asthma is going to be more complex as the cluster analytic tools are advanced.
Recently, accumulating findings suggest that the regulation of ER stress and the restoration 
of mitochondrial dysfunction are prospective molecular therapeutic approaches for various 
pulmonary disorders including bronchial asthma. More encouragingly, the inhibition of ER 
stress overcomes the failure of steroid in attenuating the severe asthmatic features of mice 
including non-Th2 neutrophilic type (similar to TAC2) as well as the eosinophilic type (simi-
lar to TAC3). Furthermore, as we described earlier, therapeutic approach to control ER stress 
is able to regulate multiple integrated signaling networks concomitantly known as the famous 
pathogenic mechanisms for steroid-resistant inflammatory responses. In addition, the link 
between ER stress and mitochondrial ROS generation is very interesting in severe asthma.
Interestingly, in non-Th2 neutrophilic severe asthma, NLRP3 inflammasome assembly is acti-
vated and consequently induces IL-1β production and release. In addition, mitochondrial 
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ROS generation and the mitochondrial DNA damage are closely associated with NLRP3 
inflammasome activation in this animal model of severe asthma. Meanwhile, in non-Th2 
eosinophilic steroid-resistant asthma induced by fungal extract, mitochondrial dysfunction 
on their dynamics or morphology as well as ROS generation is observed, which resulted in 
steroid-resistant airway inflammation and hyperresponsiveness in mice. Therefore, the res-
toration and inhibition of mitochondrial dysfunction can be a novel promising target for the 
therapeutics of severe asthma. Considering the link among ER, mitochondria, and inflamma-
some, their interconnection can be suggested as a more powerful tool for the control of severe 
asthma (Figure 1).
Despite success in mice, to date, there is the shortage of information on molecular mecha-
nisms, explaining these effects of the control for ER stress and mitochondria, and there are 
also no clinical trials that evaluate the therapeutic effects of the pharmacologic agents tar-
geting subcellular organelles in humans. In addition, since the subcellular organelles play 
essential roles in the body, the adverse effects of the pharmacologic intervention targeting ER 
or mitochondria must be considered. However, as for the adverse effects, since this therapeu-
tic approaching concept is aimed to restore the stressful or dysfunctional condition into the 
physiologic levels, not to block the function or to null, it seems to be superior to other new 
therapeutics pursuing the single specific target blockade.
In conclusion, the restoration of subcellular organelles in a disease state is a potentially excit-
ing target for developing agents to achieve better management of severe asthma in which 
steroids and other current agents are less effective.
Figure 1. Schematic diagram of the possible interconnection among endoplasmic reticulum, mitochondria, and 
inflammasome in the pathogenesis of steroid-resistant asthma.
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